ViiV Healthcare studies show 2-drug regimen of dolutegravir plus lamivudine high efficacy rates and no cases of treatment emergent resistance
LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today…